证券代码：002788 证券简称：鹭燕医药 编号：2021-002 鹭燕医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | √特定对象调研 □分析师会议 | | | 投资者关系 | □媒体采访 □业绩说明会 | | | 活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | □其他（请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 兴业证券：黄昭宇 | | | 时间 | 2021 年 7 月 29 日 | 10:30-12:00 | | | | | | 地点 | 鹭燕医药会议室 | | ...

Financial Performance - The company's operating revenue for Q3 2022 was CNY 4,982,869,676.98, representing a 10.04% increase compared to the same period last year[6] - The net profit attributable to shareholders for Q3 2022 was CNY 82,094,778.88, an increase of 3.61% year-on-year[6] - The company reported a basic earnings per share of CNY 0.21 for Q3 2022, up 5.00% from the same period last year[6] - The net profit for the third quarter of 2022 was CNY 251,958,323, an increase of 9.8% compared to CNY 229,058,402 in the same period last year[25] - The total comprehensive income for the quarter was CNY 255,741,712.26, compared to CNY 228,724,810.17 in the prior year, indicating a growth of 11.8%[25] - The company's total profit for the quarter was CNY 332,785,948.04, compared to CNY 305,016,168.31 in the previous year, marking an increase of 9.1%[25] Cash Flow and Assets - The net cash flow from operating activities increased by 123.80% year-on-year, indicating improved operational efficiency and effective cash management[10] - The net cash flow from operating activities was CNY 92,154,381.20, a significant improvement from a negative cash flow of CNY -387,139,805.67 in the previous year[26] - Cash and cash equivalents at the end of the period were CNY 286,140,227.71, down from CNY 374,128,456.22 at the end of the previous year[27] - The company incurred a net cash outflow from investing activities of CNY -208,475,358.79, slightly improved from CNY -214,096,083.22 in the previous year[27] - The net cash flow from financing activities was CNY 94,556,945.34, a decrease from CNY 500,284,035.29 in the same period last year[27] - The total assets at the end of the reporting period were CNY 10,754,928,476.53, reflecting a 7.63% increase from the previous year[6] Shareholder Information - The total number of common stock shareholders at the end of the reporting period is 28,361[12] - Xiamen Maidi Technology Co., Ltd. holds 35.53% of shares, totaling 138,030,674 shares, with 35,907,834 shares pledged[12] - The top 10 shareholders include Xiamen Mingyuan Hongqiao High-tech Venture Capital Partnership with 1.51% (5,881,192 shares) and individual shareholder Li Weiyang with 1.27% (4,936,545 shares)[12] - The total number of shareholders with voting rights restored for preferred shares is 0[13] - The company has reported no participation in margin financing activities among the top 10 shareholders[12] Legal Matters - The company has ongoing legal matters related to its subsidiary Chengdu Hechuang Pharmaceutical Group, involving a total claim of 23.1 million RMB for breach of contract[17] - Chengdu Hechuang has received bankruptcy distribution payments totaling 78.005 million RMB and 55.3911 million RMB from the bankruptcy administrator of Guizhou Dechangxiang Pharmaceutical Co., Ltd.[15] - The company is actively pursuing legal actions to recover losses from Guizhou Mingrun Construction Engineering Co., Ltd., with a claim of 39.6973 million RMB plus interest[18] - The company has a total of 6,000,000 RMB in bank deposits seized as part of the enforcement of a court ruling related to the bankruptcy case[15] - The company is coordinating with multiple parties to resolve execution-related matters and ensure that collateral is prioritized for debt repayment[16] Investments and Growth - The company’s long-term borrowings increased by 49.06% to CNY 333,119,800.00, primarily due to new project loans[9] - The company’s investment properties increased by 406.86% to CNY 24,936,400.00, attributed to acquisitions through judicial auctions[9] - The company has made significant investments in ongoing projects, including modern Chinese medicine production and new pharmaceutical facilities[9] Operating Costs - Total operating costs amounted to ¥13,967,712,770.29, up 10.15% from ¥12,679,853,348.75 year-on-year[24] - Operating profit for the period was ¥331,260,720.17, a slight increase from ¥305,319,751.77 in the previous year[24]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 9,340,896,235.85, representing a 10.22% increase compared to CNY 8,474,180,571.65 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was CNY 168,764,960.24, up 10.34% from CNY 153,140,313.21 in the previous year[20]. - Basic and diluted earnings per share both increased to CNY 0.43, reflecting a growth of 10.26% compared to CNY 0.39 in the previous year[20]. - The company reported a net profit margin of 16% for the first half of 2022, compared to 15% in the first half of 2021, indicating a slight improvement in profitability[108]. - The company reported a net profit margin of 22% for the first half of 2022, indicating strong operational efficiency[109]. - The company reported a net profit of 865.15 million for the first half of 2022, down from 1,000 million in the first half of 2021, indicating a decrease of about 13.5%[111]. - The company reported a total comprehensive income of CNY 171,030,225.87, compared to CNY 149,093,839.88 in the previous year, an increase of 14.7%[160]. - The total comprehensive income for the first half of 2022 was 245.1 million yuan, compared to 167.2 million yuan in the same period of the previous year, representing an increase of approximately 46.6%[179]. Cash Flow and Assets - The net cash flow from operating activities improved significantly, reaching CNY 18,435,029.72, a 106.00% increase from a negative CNY 296,848,523.55 in the same period last year[20]. - The company's cash flow from operating activities improved significantly, generating ¥18,435,029.72 compared to a negative cash flow of -¥307,051,752.30 in the previous year, marking a 106.00% increase[52]. - The company's cash and cash equivalents increased by 134.04% to ¥60,851,641.22 from a negative balance of -¥178,750,661.72 in the previous year[52]. - The total assets at the end of the reporting period were CNY 10,598,189,169.63, a 6.06% increase from CNY 9,992,695,467.80 at the end of the previous year[20]. - The total assets at the end of the reporting period were 5.2 billion yuan, with total liabilities of 2.4 billion yuan[171]. - The total assets at the end of the first half of 2022 were 1,230 million yuan, up from 1,159 million yuan at the end of the previous year, indicating a growth of approximately 6.1%[180]. Market Position and Strategy - The company ranked 15th among the top 100 pharmaceutical wholesale enterprises in China in 2021, maintaining its position as the largest pharmaceutical distribution company in Fujian Province for thirteen consecutive years[28]. - The company is expanding its market presence through acquisitions in Sichuan, Jiangxi, and Hainan provinces, enhancing its competitive edge in these regions[31]. - The company aims for the top 100 pharmaceutical wholesale enterprises to account for 98% of the market by 2025, indicating a trend towards increased market concentration[29]. - The company is actively investing in traditional Chinese medicine, with ongoing projects to expand production capacity and national distribution of Chinese herbal pieces[32]. - The company is transitioning from a distributor to a comprehensive service provider by enhancing its capabilities in pharmaceutical services, market access, and terminal marketing[34]. - The company is exploring market expansion strategies, with plans to increase its presence in three new regions by the end of 2022[109]. - The company is exploring potential mergers and acquisitions to bolster its market position and enhance product offerings[110]. Operational Efficiency and Cost Management - The gross margin for the first half of 2022 was reported at 24%, slightly up from 23% in the previous year, indicating improved cost management[108]. - The gross margin for the first half of 2022 improved to 24%, reflecting better cost management and pricing strategies[114]. - The company aims to reduce operational costs by 5% through improved supply chain management initiatives[113]. - The company has set a target to reduce operational costs by 5% over the next year through process optimization[114]. - The company has implemented a centralized procurement mechanism for bulk goods, enhancing bargaining power with suppliers and reducing procurement costs[46]. Research and Development - Research and development expenses increased to 288.83 million in the first half of 2022, up from 250 million in the same period of 2021, highlighting a focus on innovation[108]. - The R&D budget for 2022 has been increased to 950 million, representing a 20% increase from the previous year, to support new technology initiatives[109]. - The company has allocated 270 million yuan for research and development in the current fiscal year[173]. - The company has allocated 1.1 million CNY for new technology development in the upcoming fiscal year[176]. - The company has initiated a new strategy focusing on enhancing its research and development capabilities to innovate and improve product offerings[179]. Social Responsibility and Community Engagement - The company is committed to social responsibility, actively participating in the fight against COVID-19 by supplying necessary medical materials[33]. - The company supplied nearly 7 million bags of traditional Chinese medicine during the COVID-19 outbreak in Fujian Province, covering nearly 1 million people in quarantine areas and frontline medical workers[85]. - The company delivered 30.53 million COVID-19 test kits in the first half of 2022, fulfilling its social responsibility in combating the pandemic in Fujian Province[85]. - The company actively participated in the centralized procurement and distribution of COVID-19 related testing reagents organized by health authorities in Fujian Province[85]. Risks and Challenges - The company faces intensified market competition, particularly in the pharmaceutical distribution sector, which may impact its market share[70]. - The ongoing price reduction policies in the healthcare sector could compress the company's profit margins if sales volumes do not increase accordingly[71]. - The company faces goodwill impairment risks if acquired companies do not meet performance expectations, which could significantly impact overall performance[76]. - The company's operating cash flow is lower than net profit due to long collection cycles from medical institutions and short credit periods from suppliers, leading to potential liquidity pressures[76]. Governance and Compliance - The financial report was approved by the board of directors on August 19, 2022, indicating a structured governance process[188]. - The company prepares financial statements based on the going concern assumption and adheres to the accounting standards and guidelines set forth by the relevant authorities[190]. - The company's financial statements comply with the requirements of the accounting standards, accurately reflecting its financial position and operating results[193].

证券代码：002788 证券简称：鹭燕医药 公告编号：2022-019 鹭燕医药股份有限公司 关于参加厦门辖区上市公司 2021 年年报业绩说明会 暨投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和 完整，没有虚假记载、误导性陈述或重大遗漏。 鹭燕医药股份有限公司（以下简称"公司"）已于 2022 年 4 月 26 日披露了《2021 年年 度报告》全文及摘要。为进一步加强与投资者的互动交流，使广大投资者能更深入全面地了 解公司情况，公司将参加由厦门证监局指导、厦门上市公司协会与深圳市全景网络有限公司 联合举办的"厦门辖区上市公司 2021 年年报业绩说明会暨投资者网上集体接待日"活动， 现将相关事项公告如下： 一、活动召开时间、方式、平台 1、活动时间：2022 年 5 月 10 日（星期二）14:30-16:00； 2、活动方式：网络文字互动方式； 3、活动平台：全景网投资者关系互动平台（http://ir.p5w.net）。 二、参加人员 出席本次网上集体接待日活动的人员有：公司董事长兼总经理吴金祥先生、董事、副总 经理兼财务总监杨聪金女士、独立董事叶少琴女士、董事会 ...

Financial Performance - The company's operating revenue for 2021 was CNY 17,545,397,267, representing a 12.94% increase compared to CNY 15,531,278,461 in 2020[19]. - The net profit attributable to shareholders for 2021 was CNY 305,870,612.74, an increase of 14.72% from CNY 267,525,983.23 in 2020[19]. - The net profit after deducting non-recurring gains and losses was CNY 287,727,554.44, reflecting a 12.22% increase from CNY 256,390,986.49 in 2020[19]. - Basic earnings per share for 2021 was CNY 0.79, an increase of 6.76% compared to CNY 0.74 in 2020[20]. - Total assets at the end of 2021 reached CNY 9,992,695,467, representing a 16.59% increase from CNY 8,434,883,342 at the end of 2020[20]. - The company reported a net profit attributable to shareholders of 305,870,612.74 CNY for 2021, with a parent company net profit of 283,288,752.67 CNY[158]. Cash Flow and Investments - The net cash flow from operating activities was negative CNY 372,020,787.9, a significant decrease of 715.99% compared to a positive CNY 77,222,645.26 in 2020[19]. - The company reported a net cash flow from operating activities of CNY -509,771,160.96 in Q1 2021, indicating cash flow challenges[24]. - The net cash increase in cash and cash equivalents was -170,397,500.87 yuan, a decline of 188.19% from the previous year[74]. - The total investment amount for the reporting period reached CNY 935,170,748.33, representing a year-on-year increase of 156.85% compared to CNY 364,090,130.64[82]. - The company has cumulatively invested CNY 394,200,000 in its wholly-owned subsidiaries, with CNY 71,712,000 approved for future capital increases[83]. Business Expansion and Acquisitions - The company completed the acquisition of 100% equity in Luyan (Fujian) Group Co., Ltd. in October 2021, which required retrospective adjustments to previous financial data[18]. - The company is actively expanding its pharmaceutical distribution business through acquisitions in Sichuan, Jiangxi, and Hainan provinces[35]. - The company has acquired stakes in Anhui Shouyuan Pharmaceutical and Sichuan Yatong Pharmaceutical, although these acquisitions had no significant impact on overall performance[100]. - The company completed the acquisition of 100% equity in Xiamen Luyuan Biotechnology Co., Ltd. in October 2021, which is now considered a subsidiary[163]. Market Position and Strategy - The company ranked 16th among the top 100 pharmaceutical wholesale enterprises in China in 2020, maintaining its position as the largest pharmaceutical distributor in Fujian Province[31]. - The pharmaceutical retail market sales in China reached CNY 5,119 billion in 2020, with continued growth expected in 2021[32]. - The company is positioned to benefit from the "14th Five-Year Plan" and the "Healthy China" strategy, which aims to enhance the pharmaceutical supply chain[33]. - The company is focusing on digital transformation and enhancing service capabilities to adapt to the evolving pharmaceutical retail landscape[32]. - The company plans to implement a "631" development strategy, focusing on health services and expanding market share both within and outside Fujian province[104]. Risk Management and Compliance - The company emphasizes the importance of risk factors and countermeasures in its future development outlook[4]. - The company emphasizes the importance of risk management and compliance to mitigate potential investment and acquisition risks[106]. - The company has established a strict accounts receivable management system, but high accounts receivable levels could impact cash flow if not managed effectively[110]. - The company has committed to ensuring that related transactions do not harm the legal rights of the company and its shareholders[177]. Corporate Governance - The company maintains an independent governance structure, with no significant discrepancies from legal requirements, ensuring effective risk management and operational efficiency[118]. - The company has a complete and independent business system for pharmaceutical distribution and retail, with no reliance on the controlling shareholder[122]. - The company has a diverse management team with various roles, including a chairman, general manager, and multiple vice presidents[125]. - The company has established a remuneration management system linking senior management's compensation to company performance[138]. Employee Management and Training - The total number of employees at the end of the reporting period was 5,165, with 4,916 from major subsidiaries and 249 from the parent company[153]. - The professional composition includes 2,254 sales personnel, 940 warehouse personnel, and 383 management personnel[154]. - Training plans have been established to improve management and employee skills, covering topics such as corporate culture and compliance management[156]. Product and Service Development - The medical device business saw a sales revenue growth of 20.29% year-on-year, driven by the expansion of low-consumption products related to the pandemic[39]. - The company delivered 16.46 million COVID-19 test kits in Fujian province, generating sales revenue of CNY 209 million[39]. - The company is investing CNY 56,000 million in the "Modern Traditional Chinese Medicine Production Project" to enhance its production and sales capabilities in traditional Chinese medicine[41]. Financial Management - The company aims to enhance its financial management capabilities and optimize resource allocation to support sustainable growth[106]. - The company has implemented strict cost control measures, resulting in savings on project construction costs and additional interest income from idle funds[94]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 16.95 million[139].

鹭燕医药股份有限公司 2022 年第一季度报告全文 证券代码：002788 证券简称：鹭燕医药 公告编号：2022012 鹭燕医药股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 2021 年 10 月，公司收购鹭燕（福建）集团有限公司 100%股权，本次收购事项属于同一控制下企业合并，公司根据《企业 会计准则》等相关规定，相应追溯调整以前年度会计数据。 | | | 度末增减 | | | --- | --- | --- | --- | | | 调整前 调整后 | 调整后 | | ...

Financial Performance - The company's operating revenue for Q3 2021 was CNY 4,528,141,625.96, representing an increase of 8.12% compared to the same period last year[4] - The net profit attributable to shareholders was CNY 75,396,481, a decrease of 8.63% year-on-year[4] - The basic earnings per share (EPS) decreased by 20.83% to CNY 0.19 from CNY 0.25 in the same period last year[4] - Total operating revenue for the period reached ¥13,002,322,197.61, compared to ¥11,403,022,961.83 in the previous period, reflecting a significant increase[21] - Net profit for the period was ¥225,412,641.24, compared to ¥211,946,770.60 in the previous period, showing a growth in profitability[23] - The total comprehensive income attributable to the parent company was CNY 228,203,202.40, an increase from CNY 211,882,888.10 in the previous period[24] - Basic and diluted earnings per share were both CNY 0.59, down from CNY 0.61 in the previous period[24] Assets and Liabilities - The total assets at the end of the reporting period were CNY 9,587,575,906.38, reflecting a growth of 13.67% compared to the end of the previous year[5] - The company's total assets increased to ¥9,587,575,906.38 from ¥8,434,883,342.25, indicating strong asset growth[20] - Total liabilities rose to ¥7,047,272,242.19 from ¥6,028,634,871.80, reflecting an increase in financial obligations[19] - Current liabilities reached ¥5,815,299,887.25, including short-term borrowings of ¥3,344,974,411.97 and accounts payable of ¥1,591,374,526.41[31] - Total liabilities were reported at ¥6,028,634,871.80, with non-current liabilities at ¥213,334,984.55[32] - Shareholders' equity totaled ¥2,406,248,470.45, with retained earnings of ¥1,098,667,059.56[32] Cash Flow - The cash flow from operating activities showed a net outflow of CNY 376,999,100, a decrease of 7.50% compared to the same period last year[4] - Cash inflow from operating activities totaled CNY 13,934,872,693.87, compared to CNY 12,199,499,798.07 in the previous period, representing an increase of approximately 14.2%[26] - Cash outflow from operating activities was CNY 14,311,871,826.50, up from CNY 12,550,194,101.61, leading to a net cash flow from operating activities of CNY -376,999,132.63[27] - The ending balance of cash and cash equivalents was CNY 373,952,346.20, down from CNY 354,059,041.08 in the previous period[28] - The company reported a decrease in cash and cash equivalents of CNY -99,824,238.31 for the period[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 28,584[11] - Xiamen Mediken Technology Co., Ltd. holds 35.53% of shares, totaling 138,030,674 shares[11] - The company has a total of 138,030,674 unrestricted shares held by its top shareholders[11] - The company's financial performance and shareholder structure indicate a concentration of ownership, with the top shareholder holding over 35%[11] Legal Matters - The company has initiated legal actions to recover losses amounting to ¥2,310 million due to breaches of contract related to its subsidiary Chengdu Hechuang[14] - Chengdu Hechuang has filed a lawsuit seeking compensation of ¥39,697,300 and interest from Guizhou Mingrun Construction Engineering Co., Ltd.[15] - The company is involved in ongoing legal proceedings regarding guarantees and debts related to its subsidiary, impacting its financial position[13] - The company is actively pursuing recovery of debts through court actions, reflecting a strategic focus on financial recovery[14] Asset Management - The company reported a 65.35% increase in credit impairment losses, attributed to longer collection periods from medical institution clients due to increased sales in regions like Sichuan, Jiangxi, and Hainan[9] - The company’s contract liabilities increased by 115.42% to CNY 40,039,000, primarily due to increased prepayments for medical equipment[9] - The company’s intangible assets increased by 49.40% to CNY 169,168,100, mainly due to the acquisition of land use rights for a project[9] - Inventory levels increased to ¥2,205,183,924.97 from ¥2,028,122,409.74, suggesting potential growth in sales or production[18] Research and Development - The company reported a research and development expense of ¥2,289,641.11, down from ¥2,742,498.28 in the previous period, indicating a reduction in R&D investment[21] Accounting and Standards - The report indicates that the third-quarter financial results were not audited[33] - The company has implemented new leasing standards affecting the recognition of right-of-use assets and lease liabilities[33]

证券代码：002788 证券简称：鹭燕医药 公告编号：2021-038 鹭燕医药股份有限公司 关于参加 2021 年度厦门辖区上市公司投资者网上集 体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和 完整，没有虚假记载、误导性陈述或重大遗漏。 鹭燕医药股份有限公司（以下简称"公司"）为进一步加强与投资者的互动交流，使广 大投资者能更深入全面地了解公司情况，公司将参加由厦门证监局指导、厦门上市公司协会 与深圳市全景网络有限公司联合举办的"2021 年度厦门辖区上市公司投资者网上集体接待 日"活动，现将相关事项公告如下： 一、活动召开时间和方式 1、召开时间：2021 年 9 月 7 日（星期二）15:00-17:00。 2、召开方式：本次活动将通过深圳市全景网络有限公司提供的网上平台进行，投资者 可以登录"全景网投资者关系互动平台"（http://ir.p5w.net）参与本次互动交流。 二、参加人员 出席本次网上集体接待日活动的人员有：公司董事长兼总经理吴金祥先生、董事、副总 经理兼财务总监杨聪金女士、董事会办公室主任兼董事会秘书叶泉青先生。 欢迎广大投资者积极参与。 特此公告。 鹭燕医 ...

Financial Performance - The company's operating revenue for the first half of 2021 was ¥8,474,180,571.65, representing a 17.45% increase compared to ¥7,214,832,652.33 in the same period last year[20]. - The net profit attributable to shareholders was ¥153,140,313.21, up 17.77% from ¥130,029,913.14 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥150,932,099.04, reflecting an 18.94% increase from ¥126,900,039.34[20]. - The basic earnings per share for the reporting period was ¥0.39, a 5.41% increase compared to ¥0.37 in the previous year[20]. - The diluted earnings per share for the reporting period was also ¥0.39, reflecting a 5.41% increase from ¥0.37[20]. - The total operating revenue for the first half of 2021 reached ¥8,474,180,571.65, an increase from ¥7,214,832,652.33 in the same period of 2020[154]. - The total profit for the first half of 2021 was CNY 200,676,471.04, compared to CNY 178,845,302.60 in the same period of 2020, indicating an increase of 12.2%[156]. - The total comprehensive income for the first half of 2021 was CNY 149,286,760.49, compared to CNY 130,420,115.10 in the same period of 2020, representing an increase of 14.4%[157]. - The company reported a net income of 990 million for the first half of 2021, compared to 500 million in the previous year, representing an increase of 98%[111]. Cash Flow and Financial Position - The net cash flow from operating activities was -¥296,848,523.55, a decline of 164.26% compared to -¥112,330,291.44 in the previous year[20]. - The company's cash and cash equivalents decreased to ¥393,138,413.60, accounting for 4.34% of total assets, down from 7.06% in the previous year[59]. - The total liabilities increased to CNY 6,600,794,889.83 from CNY 6,028,634,871.80, which is an increase of approximately 9.5%[148]. - The company's short-term borrowings rose to CNY 3,863,810,473.18, up from CNY 3,344,974,411.97, reflecting an increase of about 15.5%[148]. - The total cash and cash equivalents at the end of the period were 165,023,575.97 yuan, down from 230,215,627.79 yuan year-over-year[168]. - The total liabilities reached CNY 2,367,085,543.91, compared to CNY 2,029,650,794.26 at the end of 2020[153]. - The company reported a significant increase in accounts receivable, which rose to CNY 218,163,069.38 from CNY 185,467,126.00[151]. - The total equity attributable to the parent company at the end of the first half of 2021 was 2,406 million yuan, a decrease of 9,927 million yuan compared to the previous period[170]. Market and Operational Developments - The company maintained a leading position in the pharmaceutical distribution market in Fujian Province, with a 14.66% year-on-year increase in revenue from its operations in the province[34]. - Revenue from the company's operations outside Fujian Province grew by 26.72% during the reporting period[34]. - The company is actively expanding its pharmaceutical distribution network in Sichuan, Jiangxi, and Hainan provinces through mergers and acquisitions[30]. - The company is focusing on enhancing its capabilities in pharmaceutical services, access, and terminal marketing to strengthen its core competitiveness in the distribution sector[34]. - The company is constructing modern pharmaceutical logistics centers in Sichuan and Jiangxi to enhance storage and distribution capabilities[39]. - The company has established a distribution and logistics network covering over 90% of medical institutions in Sichuan, Jiangxi, and Hainan provinces[40]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio, with a budget of 3,000 million earmarked for strategic acquisitions[110]. Risks and Challenges - The company faces risks from intensified market competition and potential loss of its leading position in the pharmaceutical distribution industry in Fujian Province[71]. - The company has a risk of inventory loss due to the need for maintaining sufficient stock levels and strict expiration date management[73]. - The company faces significant risks related to product quality compliance, which could lead to substantial administrative fines or loss of production qualifications if regulatory requirements are not met[76]. - Operating cash flow is lower than net profit due to long collection cycles from medical institutions and short credit terms from suppliers, which may pressure the company's liquidity and expansion capabilities[76]. - The company has established a strict accounts receivable management system, but faces risks if major clients delay payments[72]. Legal and Compliance Matters - Chengdu Hechuang Pharmaceutical Group Co., Ltd. is involved in a lawsuit with Guizhou Mingrun Construction Engineering Co., Ltd. regarding a claim for the return of a performance bond of 15 million yuan and interest, along with a penalty of 8 million yuan and compensation for losses of 100,000 yuan (tentative)[92]. - The company has a contingent liability of 266.2449 million yuan related to the ongoing litigation[92]. - The court has ruled that Guizhou Mingrun Construction Engineering Co., Ltd. is liable for breach of contract, and the case is currently in the second instance of appeal[93]. - The company is appealing a court decision regarding a payment of CNY 1,000 million related to a share transfer[126]. Shareholder and Equity Information - The total number of shares is 388,516,736, with 9,851,962 shares subject to limited sale conditions, representing 2.54% of total shares[129]. - The largest shareholder, Xiamen Maidi Kenke Technology Co., Ltd., holds 35.53% of the shares, totaling 138,030,674 shares[134]. - The company has not reported any changes in the number of shares or any share repurchase progress during the reporting period[129]. - The total number of ordinary shareholders at the end of the reporting period is 29,559[134]. Strategic Initiatives - The company plans to invest 560 million RMB in a modern Chinese medicine production project in Bozhou, with a total construction area of approximately 296,000 square meters[37]. - The company is focusing on sustainable development strategies and has implemented effective operational systems and internal control mechanisms to manage risks[47]. - The company has adopted a merger and acquisition strategy for regional expansion, enhancing operational efficiency and reducing management costs through resource sharing[46]. - The company plans to enhance its online sales platform, aiming for a 30% increase in e-commerce revenue by the end of 2021[114].

Financial Performance - The company's operating revenue for Q1 2021 was ¥4,165,230,014.41, representing a 23.93% increase compared to the same period last year[8]. - Net profit attributable to shareholders was ¥64,700,746.54, reflecting a 26.32% year-over-year growth[8]. - The net profit after deducting non-recurring gains and losses was ¥64,624,978.47, which is a 31.46% increase from the previous year[8]. - The basic earnings per share (EPS) increased to ¥0.17, up 13.33% from ¥0.15 in the same quarter last year[8]. - The total profit for the quarter was CNY 83,805,463.91, an increase of 23.5% from CNY 67,836,575.86 year-on-year[46]. - Net profit for the quarter reached CNY 61,189,804.43, representing a 24.2% increase from CNY 49,260,498.13 in the previous year[46]. - The company reported a total comprehensive income of CNY 61,336,866.01, up from CNY 49,895,800.78 in the previous year[47]. Assets and Liabilities - The total assets at the end of the reporting period were ¥8,908,751,620.19, a 5.62% increase from the end of the previous year[8]. - The company's total liabilities amounted to CNY 6,434,966,283.73, up from CNY 6,028,634,871.80 year-over-year, indicating a growth of approximately 7%[39]. - The total owner's equity rose to CNY 2,473,785,336.46, up from CNY 2,406,248,470.45, which is an increase of approximately 2.8%[39]. - Total current liabilities were CNY 5,815,299,887.25, remaining unchanged from the previous period[60]. - Total non-current liabilities increased to CNY 213,334,984.55, with an adjustment of CNY 105,302,597.44[61]. Cash Flow - The cash flow from operating activities showed a net outflow of ¥509,771,160.96, a decrease of 36.30% compared to the previous year[8]. - The total cash inflow from operating activities was CNY 4,540,455,694.72, an increase of 23.6% compared to CNY 3,671,739,573.99 in the previous period[53]. - The net cash outflow from operating activities was CNY -509,771,160.96, worsening from CNY -374,020,009.96 in the previous period[53]. - Cash inflow from financing activities totaled CNY 2,392,346,797.48, a slight decrease of 3.9% from CNY 2,490,391,985.12 in the previous period[54]. - The cash and cash equivalents at the end of the period were CNY 407,616,675.44, a decrease from CNY 413,284,226.01 in the previous period[54]. Investments and Projects - The construction in progress increased by 41.77% to ¥80,916,000, mainly due to investments in the logistics center project of Chengdu Hechuang Pharmaceutical Technology Co., Ltd.[16]. - The intangible assets rose by 42.63% to ¥161,504,900, attributed to the acquisition of land use rights for the Luyan Bozhou Modern Chinese Medicine Project[16]. - The company allocated RMB 12,633.36 million to the Fuzhou warehousing center project and RMB 11,008.86 million to the Putian logistics center project[26]. - The retail chain expansion project has completed construction with a total investment of CNY 8,000 million, achieving a progress rate of 71.89%[27]. - The company has made significant investments in expanding its warehousing and logistics capabilities, including projects in Xiamen and Fuzhou[26]. Legal and Compliance - The company signed a settlement agreement with multiple parties to prioritize project sales revenue for debt repayment[18]. - The company has initiated litigation against the equity transferor and guarantor of Chengdu Hechuang Pharmaceutical Group for breach of contract, claiming a total of RMB 43,623.1 million in damages[19]. - The company has received a court ruling requiring Guizhou Mingrun Construction Engineering Co., Ltd. to return a performance deposit of RMB 15 million[20]. - The company is currently in the process of appealing a court decision regarding a claim for remaining equity transfer payments of RMB 10 million[20]. Future Outlook - Future outlook includes potential market expansion and new product development, although specific figures or timelines were not provided in the report[44]. - The company has not reported any new product developments or market expansions in this quarter[68].